Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Geriatrics | Gynecology | Internal Medicine | Orthopedics | Pharmacy | Rheumatology | Journal

Back to Journal Articles

Abaloparatide Reduces Fracture Risk in Women With Osteoporosis

Last Updated: August 17, 2016.

In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo, according to a study published in the Aug. 16 issue of the Journal of the American Medical Association.

WEDNESDAY, Aug. 17, 2016 (HealthDay News) -- In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo, according to a study published in the Aug. 16 issue of the Journal of the American Medical Association.

Paul D. Miller, M.D., of the Colorado Center for Bone Research in Lakewood, and colleagues randomly assigned 2,463 postmenopausal women with osteoporosis to receive daily injections of abaloparatide, teriparatide, or a placebo for 18 months. Their average age was 69.

The researchers found that among the 1,901 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo. Fewer women on the injectable drug abaloparatide had vertebral fractures (0.58 percent) than women receiving a placebo (4.22 percent), and slightly fewer than those taking teriparatide (0.84 percent). Women taking abaloparatide also had fewer other types of fractures (2.7 percent) than those who got a placebo (4.7 percent), and slightly fewer than those on teriparatide (3.3 percent). Fewer cases of hypercalcemia occurred among women taking abaloparatide (3.4 percent) than teriparatide (6.4 percent).

"The way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems, but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use," write the authors of an accompanying editorial.

The study was funded Radius Health, the manufacturer of abaloparatide.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)


Previous: Residents Often Order Perceived Unnecessary Lab Tests Next: Duration of Adult Obesity Affects Cancer Risk in Women

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: